Publicaciones en colaboración con investigadores/as de Karolinska Institute (4)

2021

  1. Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

    Cardiovascular Diabetology, Vol. 20, Núm. 1

2020

  1. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

    The Lancet Diabetes and Endocrinology, Vol. 8, Núm. 7, pp. 606-615

2018

  1. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study

    Journal of the American College of Cardiology, Vol. 71, Núm. 23, pp. 2628-2639

  2. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL

    Journal of the American College of Cardiology, Vol. 71, Núm. 22, pp. 2497-2506